28 Oct, 2016 Clinical Benefits of Tramiprosate in Alzheimer’s Disease Are Associated with Higher Number of APOE4 Alleles: The “APOE4 Gene-Dose Effect” alzheon2019-09-23T12:10:50-04:00October 28th, 2016| Read More
24 Jul, 2016 Clinically Meaningful Cognitive and Functional Improvements with Tramiprosate In Alzheimer’s Disease (AD) Patients with APOE4/4 Genotype: Subgroup Analyses from Two Phase 3 Studies alzheon2019-09-23T12:10:52-04:00July 24th, 2016| Read More
24 Jul, 2016 Phase 1 Development Of ALZ-801, a Novel Beta Amyloid Anti-aggregation Prodrug of Tramiprosate With Improved Drug Properties, Supporting Bridging to the Phase 3 Program alzheon2019-09-23T12:10:53-04:00July 24th, 2016| Read More
11 Mar, 2016 Efficacy of tramiprosate in APOE4 heterozygous patients with mild to moderate AD: combined sub-group analyses from two Phase 3 trials alzheon2019-09-23T12:10:53-04:00March 11th, 2016| Read More
11 Mar, 2016 Tramiprosate, an oral amyloid anti-aggregation agent, shows robust cognitive efficacy in APOE4/4 homozygous AD patients: efficacy and safety analyses from two Phase 3 trials alzheon2019-09-23T12:10:53-04:00March 11th, 2016| Read More
27 Oct, 2015 Cognitive and Functional Efficacy of Tramiprosate in APOE4+ Patients with Mild to Moderate Alzheimer’s Disease: Subgroup Analyses of the Phase 3 North American and European Trials alzheon2019-09-23T12:10:53-04:00October 27th, 2015| Read More
20 Mar, 2015 Analyses of tramiprosate Phase 3 trials show improvement in cognition and function in APOE4 positive alzheimer’s disease subjects reaching 4 point improvement from placebo on ADAS-cog in homozygous APOE4 subjects, and support development of ALZ-801, a novel prodrug of tramiprosate with optimized drug properties alzheon2019-09-23T12:10:54-04:00March 20th, 2015| Read More
